Research and development activity of Covid-19 vaccine, drugs and medical devices brought under CSR Policy of companies
MINISTRY OF CORPORATE AFFAIRS
New Delhi, the 24th August, 2020
G.S.R. 526(E).—In exercise of the powers conferred by section 135 and sub-sections (1) and (2) of section 469 of the Companies Act, 2013 (18 of 2013), the Central Government hereby makes the following rules further to amend the Companies (Corporate Social Responsibility Policy) Rules, 2014, namely:-
1. Short title and commencement.—(1) These rules may be called the Companies (Corporate Social Responsibility Policy) Amendment Rules, 2020.
(2) They shall come into force on the date of their publication in the Official Gazette.
2. In the Companies (Corporate Social Responsibility Policy) Rules, 2014 (hereinafter referred to as the said rules), in rule 2, in sub-rule (1), in clause (e), the following proviso shall be inserted, namely:-
“Provided that any company engaged in research and development activity of new vaccine, drugs and medical devices in their normal course of business may undertake research and development activity of new vaccine, drugs and medical devices related to COVID-19 for financial years 2020-21, 2021-22 and 2022-23 subject to the conditions that-
(i) such research and development activities shall be carried out in collaboration with any of the institutes or organisations mentioned in item (ix) of Schedule VII to the Act.
(ii) details of such activity shall be disclosed separately in the Annual Report on CSR included in the Board’s Report”.
3. In the said rules, in rule 4, in sub-rule 1, the words “excluding activities undertaken in pursuance of its normal course of business” shall be omitted.
4. In the said rules, in rule 6, in sub-rule (1),—
(i) first proviso shall be omitted;
(ii) In the second proviso, the word “further” shall be omitted.
GYANESHWAR KUMAR SINGH, Jt.Secy.
Note:The principal rules were published in the Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i), videnumber G.S.R. 129(E), dated the 27th February, 2014 and were subsequently amended by notification number G.S.R. 644(E), dated the 12th September, 2014, notification number G.S.R. 43(E), dated the 19th January, 2015, notification number G.S.R. 540 (E), dated the 23rd May, 2016 and notification number G.S.R. 895(E), dated the 19th September, 2018.
Download Notification Click Here >>
- SEBI warns Investment Advisers dealing in unregulated products
- Multipurpose Empanelment Form (MEF) for year 2021-22 available at meficai.org
- ICSI prescribes Due Diligence Report for Format for Listed Entities
- CBDT prescribes Form/manner of furnishing undertaking u/s 119 of Finance Act 2012
- Registration of Assignment of Receivables (Amendment) Rules 2021